The OlympiA study was a phase III, double-blind, randomized trial involving patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. This evidence concerns the gene BRCA2 and breast carcinoma.